On September 11, 2023, The U.S. Food and Drug Administration (FDA) approved and authorized for emergency use the following monovalent (single) component COVID-19 mRNA vaccines, targeted against the currently circulating Omicron subvariant XBB.1.5:
* Pfizer-BioNTech COVID-19 Vaccine 202302024 Formula): individuals 6 months and older.
* Moderna COVId-19 Vaccine (2023-2024 Formula): Individuals ages 6 months and older.
When our vaccine becomes available, we will inform you of the clinic dates and times.